Basic Xifaxan Information

• INN (International Nonproprietary Name): Rifaximin
• Brand Names Available In Australia: not specified
• ATC Code: A07AA11
• Forms & Dosages: Oral tablet 200mg, 550mg; oral suspension 100mg/5mL (oral suspension not available in all regions)
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription-only (Rx) in major markets; local status should be checked with the ARTG/PBS

Latest Research Highlights

Clinicians and patients ask: does rifaximin really work for IBS‑D, hepatic encephalopathy and travel diarrhoea?

Randomised controlled trials show benefit for IBS‑D using a 14‑day course of 550 mg three times daily, with symptom reduction for many patients and modest relapse rates after treatment cessation.

Maintenance trials in hepatic encephalopathy report benefit with chronic dosing of 550 mg twice daily, reducing recurrence of overt encephalopathy episodes in studied cohorts.

For traveller’s diarrhoea caused by non‑invasive Escherichia coli, short courses of 200 mg three times daily for three days were favoured in trials versus placebo or symptomatic therapy.

Safety datasets consistently report mainly gastrointestinal adverse events such as nausea and constipation, occasional headache and rare hypersensitivity reactions.

Because rifaximin is minimally absorbed, systemic adverse events are uncommon.

Key research gaps remain: long‑term microbiome impact, outpatient resistance surveillance and Australian post‑market reports through the TGA and PBS data streams are limited or not publicly comprehensive.

Clinicians should consult recent meta‑analyses and TGA safety notices for updates when making prescribing decisions.

Clinical Effectiveness In Australia

What should Australian clinicians expect from rifaximin in routine practice?

Local randomised trial data are limited, so Australian practice mainly extrapolates from international RCTs and registries for IBS‑D, hepatic encephalopathy and traveller’s diarrhoea.

TGA listing and PBS coverage must be checked via the Australian Register of Therapeutic Goods (ARTG) and the PBS eLookup before relying on subsidised access.

In real‑world Australian use, gastroenterologists and hepatologists commonly prescribe rifaximin for IBS‑D and maintenance of hepatic encephalopathy where clinically appropriate, with private prescriptions used if PBS coverage is absent.

TGA adverse event reports in Australia mirror international safety profiles: mainly GI upset and rare dermatologic hypersensitivity; clinicians should be alert for C. difficile when any antibiotic is used.

In rural and remote settings clinicians often monitor hepatic function more closely due to limited acute services and higher thresholds for hospital transfer.

Where available, state health registries or hospital readmission data can help quantify rifaximin’s effect on HE admissions and service planning.

Indications And Expanded Uses

Patients typically ask: what is rifaximin approved for, and when is it used off‑label?

Regulatory and trial‑based primary indications include traveller’s diarrhoea due to non‑invasive E. coli (200 mg TID for 3 days), IBS‑D symptom relief (550 mg TID for 14 days) and maintenance therapy for hepatic encephalopathy (550 mg BID chronically).

Off‑label or expanded uses encountered in Australian practice include adjunctive therapy for small intestinal bacterial overgrowth (SIBO) and carefully selected chronic diarrhoeal syndromes.

Rifaximin is contraindicated for febrile or bloody diarrhoea, where systemic antibiotics and further investigation are required.

Prescribing teams should use an indication checklist before dispensing: confirm symptom profile, rule out febrile/bloody diarrhoea, consider stool testing where appropriate, and document informed consent for off‑label uses.

Composition And Brand Landscape

Pharmacists and prescribers want clarity on brands, strengths and supply.

The active ingredient is rifaximin (INN), classified under ATC A07AA11 as an intestinal antiinfective.

Common dosage forms are oral tablets in 200 mg and 550 mg strengths, with an oral suspension available in some European markets (100 mg/5 mL) but not universally.

Global brand names include Xifaxan (200 mg, 550 mg tablets) and Normix (200 mg tablets and a 100 mg/5 mL suspension in some countries), with regional brands such as Flonorm, Rifaxen and Rifaximina in Latin America and Europe.

Salix Pharmaceuticals (Bausch Health) is the global/main manufacturer, with regional partners and emerging generics in Asia and Latin America.

Packaging and formulation differences matter for paediatric dosing because oral suspension is not available in all regions.

Contraindications And Special Precautions

Patients frequently want to know who must avoid rifaximin.

Absolute contraindications are hypersensitivity to rifaximin or other rifamycins such as rifampicin, rifabutin or rifapentine.

Rifaximin should not be used for bacterial diarrhoea with fever or bloody stools because systemic therapy and further investigation are generally required.

Use caution in severe hepatic impairment (Child‑Pugh C), where monitoring for encephalopathy and adverse effects is advised.

Prior history of Clostridioides difficile infection is an important caution as any antibiotic can predispose to recurrence.

High‑risk groups include elderly patients with polypharmacy and people with advanced liver disease, particularly where access to specialist care is limited.

Practical counselling points: watch for dizziness affecting driving or work, avoid unnecessary alcohol if hepatic impairment exists, and report severe GI symptoms immediately.

Dosage Guidelines

Patients often ask exactly how to take rifaximin for their condition.

Standard adult doses are: traveller’s diarrhoea 200 mg three times daily for three days; IBS‑D 550 mg three times daily for 14 days; and hepatic encephalopathy 550 mg twice daily for chronic maintenance.

Paediatric use has been studied in those aged 12 years and older for some indications; safety in younger children is not established.

No dose adjustment is required for renal impairment because rifaximin has minimal systemic absorption.

Severe liver impairment requires caution and closer monitoring rather than a simple dose reduction.

Missed dose advice: take as soon as remembered unless close to next dose; do not double up.

In overdose, treatment is supportive since there is no specific antidote due to low systemic absorption.

For recurrent IBS‑D, specialists may recommend retreatment intervals; pharmacists should flag repeat courses for review.

Interactions Overview

One common question is whether rifaximin interacts with other medicines.

Because rifaximin is poorly absorbed, clinically significant pharmacokinetic interactions are uncommon.

However, cross‑reactivity with other rifamycins is important for allergy and contraindication checks.

Concomitant use with other antibiotics increases the overall risk for Clostridioides difficile infection and should be considered carefully.

Pharmacists should maintain interaction alerts in dispensing software and report new signals via the TGA and local eHealth systems.

Provide printed advice on recognising C. difficile symptoms and when to seek urgent care.

Cultural Perceptions And Patient Habits

Patients often tell pharmacists they want quick relief, clear cost options and reassurance about safety.

Australian patients typically trust the pharmacist for pragmatic advice about gastrointestinal medicines and compare major retail chains for price.

Online forums report many patients experiencing symptom relief for IBS‑D after a 14‑day course, alongside concerns about cost, the need for repeat courses and long‑term effects on gut flora.

Rural and remote patients rely on regional chemists, telehealth prescribers and mail‑order dispensing for access, and community health services or Aboriginal Medical Services often assist with specialist referrals.

For culturally and linguistically diverse communities, provide plain language counselling, involve family or carers where appropriate, and offer interpreter services as needed.

• Pharmacist script: confirm indication, check allergies, outline dosing and side effects.
• Telehealth steps: electronic prescription, discuss supply and mail delivery, follow‑up plan.
• Cultural liaison: engage local AMS or community health worker for complex cases.

Address patient concerns proactively about cost, retreatment and recurrence during counselling.

Availability And Pricing Patterns

How patients pay for rifaximin in Australia depends on ARTG registration and PBS listing.

If rifaximin is not PBS‑listed for a given indication, most prescriptions are private and out‑of‑pocket costs vary by retailer and supply route.

Major retail chains and accredited online pharmacies may stock rifaximin subject to supplier imports and ARTG entries.

Telehealth platforms can issue e‑prescriptions enabling mail delivery to remote areas, which is important for rural access.

For clinic stock management in rural clinics, plan for supply lag and consider holding common pack sizes for hepatic encephalopathy maintenance patients.

In our online pharmacy, xifaxan is available without a prescription, with discreet delivery to Australia in 5-14 days.

Where a product is not locally registered or stocked, clinicians can explore special access schemes or hospital pharmacy channels for chronic HE patients.

Comparable Medicines And Preferences

Clinicians weigh alternatives on efficacy, safety, access and cost.

For hepatic encephalopathy, lactulose remains a mainstay and neomycin is sometimes used off‑label as a non‑absorbed alternative to rifaximin.

For traveller’s diarrhoea, systemic agents such as ciprofloxacin or metronidazole may be used depending on suspected pathogens, but they carry systemic side effects and resistance concerns.

For IBS‑D symptom control, agents such as loperamide and eluxadoline are options for symptomatic relief; rifaximin offers a targeted, gut‑directed antibiotic strategy with low absorption.

Use a prescriber checklist when switching: confirm indication, review comorbidities (especially liver and renal), and consider local resistance patterns where available.

Frequently Asked Questions

Is rifaximin on the PBS?

PBS listing varies by indication and over time; always check the PBS eLookup and the ARTG for the current subsidy and registration status.

Can I get Xifaxan over the counter?

No; rifaximin is prescription‑only in major markets and requires a clinician’s prescription for supply in pharmacy settings.

Is rifaximin safe in pregnancy or breastfeeding?

Human data are limited; rifaximin should be used in pregnancy or lactation only if the potential benefits justify the potential risks and after specialist advice.

How soon will I feel better for IBS‑D?

Many patients experience improvement during or shortly after a 14‑day 550 mg TID course, but some relapse and may need reassessment or retreatment planning.

What about C. difficile risk?

All antibiotics can predispose to C. difficile; advise patients to report severe diarrhoea, fever or bloody stools immediately and seek urgent care.

Guidelines For Proper Use And Pharmacy Counselling

Pharmacists should check indication, allergies and hepatic history before supplying rifaximin.

Confirm the intended use aligns with trial evidence or documented specialist rationale, especially for off‑label SIBO use.

Advise the patient on the correct regimen according to the indication and provide clear dosing instructions and expected timelines for improvement.

Storage advice: store tablets at 20–25°C, protect from moisture and keep in original packaging.

• Missed Dose: Take as soon as remembered unless it is almost time for the next dose; do not double up.
• Overdose: Provide supportive care; no specific antidote due to low absorption.
• When To Seek Help: Fever, bloody diarrhoea, severe abdominal pain, or worsening mental status for HE patients.

Provide a short printed patient handout that covers indication, dose, expected benefit timeline, common side effects and cost/PBS options.

For hepatic encephalopathy maintenance patients, coordinate with hepatology, community nursing and arrange medication reconciliation to reduce errors in polypharmacy.

Use telehealth and electronic prescription workflows for remote patients and plan for logistics if local stock is limited.

Delivery Across Australia